Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 10, Issue 10, Pages 1433-1444Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2014.947263
Keywords
cervical cancer; cutaneous T-cell lymphoma; drug repositioning; epigenetics; hydralazine; myelodysplastic syndrome; orphan drug; valproate
Funding
- Alpharma
Ask authors/readers for more resources
Introduction: DNA methylation (DNMTi) and histone deacetylase inhibitors (HDACi) are in development for cancer therapy. So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hydralazine-valproate (TRANSKRIP (TM)) is being repositioned as an oral DNMT and HDAC inhibitor. Areas covered: Brief discussion on the current status of epigenetic drugs and studies published on the preclinical and clinical development of the hydralazine-valproate combination. Expert opinion: Drug repositioning is a strategy for prompt and cost-efficient drug discovery. There is evidence that combining DNMTi with HDACi would be more efficacious than administering each agent on its own. Hydralazine-valproate is safe when used alone or in combination with chemotherapy or chemoradiation. The fact that both drugs are orally administered is another advantage over current epigenetic drugs. This combination is promising but larger studies are needed. Among these, the randomized Phase III trials in advanced and in locally advanced cervical cancer combined with chemotherapy and cisplatin-radiation respectively, would eventually confirm its efficacy. Studies on MDS and CTCL would also eventually prove the efficacy of hydralazine valproate so that in the coming years hydralazine-valproate could have a role in cancer epigenetic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available